# Diffusing Capacity of Carbon Monoxide in Assessment of COPD

Aparna Balasubramanian, MD; Neil R. MacIntyre, MD; Robert J. Henderson, MS; Robert L. Jensen, PhD; Gregory Kinney, MPH, PhD; William W. Stringer, MD; Craig P. Hersh, MD, MPH; Russell P. Bowler, MD, PhD; Richard Casaburi, PhD, MD; MeiLan K. Han, MD; Janos Porszasz, MD, PhD; R. Graham Barr, MD, DrPH; Barry J. Make, MD; Robert A. Wise, MD; and Meredith C. McCormack, MD, MHS

CHEST 2019; 156(6):1111-1119

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

© 2019 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. **DOI**: 10.1016/j.chest.2019.06.035

e-Table 1. Baseline characteristics and outcomes of participants missing % emphysema (%LAA-950)

	Total	Analysis	Missing
Characteristic	(N=1806)	(N=1564)	(N=242)
Age	68 (62, 74)	68 (62, 74)	68 (63, 74)
Male, N (%)	984 (54%)	841 (54%)	143 (59%)
Black, N (%)	356 (20%)	281 (18%)	75 (31%)
Education, N (%)			
High school, no diploma	143 (8%)	117 (7%)	26 (11%)
High school graduate or GED	442 (24%)	379 (24%)	63 (26%)
Some college or technical school, no degree	537 (30%)	467 (30%)	70 (29%)
College or technical school graduate (Bachelor's or	498 (28%)	437 (28%)	61 (25%)
Associate degree)			
Master's or doctoral degree	186 (10%)	164 (10%)	22 (9%)
BMI, kg/m <sup>2</sup>	27 (24, 31)	28 (24, 31)	27 (23, 31)
Obese (BMI≥30), N (%)	589 (33%)	519 (33%)	70 (29%)
Anemia, N (%)	240 (13%)	197 (13%)	43 (18%)
Diabetes, N (%)	282 (16%)	249 (16%)	33 (14%)
Congestive Heart Failure, N (%)	76 (4%)	60 (4%)	16 (7%)
Sleep Apnea, N (%)	312 (17%)	280 (18%)	32 (13%)
Pack years of smoking	45 (34, 63)	45 (34, 63)	46 (35, 62)
Smoking Status, N (%)	- (- / /	- (- / /	- (//
Former smoker	558 (31%)	484 (31%)	74 (31%)
Current to former smoker*	229 (13%)	191 (12%)	38 (16%)
Current smoker	1019 (56%)	889 (57%)	130 (54%)
FEV <sub>1</sub> percent predicted	69 (50, 89)	70 (51, 89)	64 (42, 83)
DLCO percent predicted	65 (49, 81)	66 (50, 82)	57 (42, 74)
$\leq 50\%$ , N(%)	479 (27%)	388 (25%)	91 (38%)
KCO percent predicted	72 (57, 87)	73 (58, 87)	67 (51, 83)
$\leq$ 50%, N(%)	304 (17%)	246 (16%)	58 (24%)
CAT	13 (7, 20)	13 (7, 20)	16 (8, 22)
SGRQ	29 (13, 46)	28 (13, 45)	35 (16, 53)
SF-36 Physical	42 (33, 50)	42 (33, 50)	39 (31, 49)
SF-36 Mental	55 (46, 60)	55 (46, 60)	55 (45, 60)
6MWD (feet)	1260 (982,	1280 (1000,	1180 (800,
onwb (reet)	1500)	1512)	1432)
<b>%LAA</b> -950 <sup>†</sup>	4 (1, 14)	4 (1, 14)	
$LAA_{950} > 5\%$ , N (%) <sup>+</sup>	741 (47%)	741 (47%)	
	. ,		
Airway Wall Thickness	1.1 (0.9, 1.2)	1.1 (0.9, 1.2)	1.1(0.9, 1.3)
TLC (L)	5.8 (4.9, 6.9)	5.8 (4.9, 6.9)	5.2 (4.1, 6.3)
Resting oxygen saturation %	96 (94, 97)	96 (94, 97)	96 (94, 98)

Values are median (interquartile range) unless otherwise specified. *BMI:* body mass index; *FEV*<sub>1</sub>: Forced expiratory volume in 1 second; *DLCO:* Diffusion capacity of the lung for carbon monoxide; *KCO:* gas transfer efficiency coefficient; *CAT:* COPD Assessment Test; *SGRQ:* St. George's Respiratory Questionnaire; *SF-36:* Short Form 36-item survey; *6MWD:* six-minute walk distance; *%LAA-950:* percent low attenuation areas  $\leq$  -950 Hounsfield units consistent with emphysema; *TLC:* total lung capacity, estimated on CT scan

\*Current to former smoker refers to the participants who went from being current smokers at the Phase I visit to former smokers by the Phase II visit.

 $^+$  %LAA  $_{950}$  characteristics are reported among the subset of participants with available HRCT data, N=1576.

Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

e-Table 2. Respiratory outcomes by DLCO and FEV<sub>1</sub> without adjustment for emphysema (%LAA-950)

	DLCO % predicted		FEV <sub>1</sub> % predicted	
Outcome	Regression Coefficient (95% CI)	p-value	Regression Coefficient (95% CI)	p-value
CAT score	0.55 (0.4, 0.7)	<.001	1.14 (0.98, 1.3)	<.001
SGRQ score	2.01 (1.58, 2.43)	<.001	3.2 (2.84, 3.57)	<.001
Activity	3.17 (2.56, 3.79)	<.001	4.28 (3.82, 4.73)	<.001
Impact	1.55 (1.14, 1.96)	<.001	2.54 (2.12, 2.96)	<.001
Symptom	1.29 (0.71, 1.87)	<.001	3.39 (3.03, 3.75)	<.001
SF-36 Physical Function	-0.92 (-1.13, -0.71)	<.001	-1.32 (-1.59, -1.06)	<.001
SF-36 Mental	-0.06 (-0.36, 0.24)	0.676	-0.14 (-0.39, 0.12)	0.291
6MWD (feet)	-52.03 (-62.83, -41.24)	<.001	-42.72 (-48.25, -37.18)	<.001
Resting SpO <sub>2</sub> %	-0.25 (-0.39, -0.12)	<.001	-0.18 (-0.23, 0.13)	<.001

Total population (n=1806) was utilized in this analysis. Associations are per 10% decrease in percent predicted DLCO or percent predicted FEV<sub>1</sub>. Models include age, sex, BMI categories, ethnicity, education, smoking pack years, smoking status, anemia status, diabetes status, congestive heart failure status, sleep apnea status, % predicted FEV<sub>1</sub>, and % predicted DLCO. *95% CI:* 95% confidence interval; *CAT:* COPD Assessment Test; *SGRQ:* St. George's Respiratory Questionnaire; *SF-36:* Short Form 36-item survey; *6MWD:* six-minute walk distance; *SpO*<sub>2</sub> %: oxygen saturation

e-Table 3. Respiratory outcomes by KCO and FEV1 with adjustment for emphysema (%LAA-950)

	KCO % predicted		FEV <sub>1</sub> % predicted	
Outcome	Regression Coefficient (95% CI)	p-value	Regression Coefficient (95% CI)	p-value
CAT score	0.59 (0.39, 0.79)	<.001	1.31 (1.1, 1.51)	<.001
SGRQ score	1.6 (1.15, 2.05)	<.001	3.39 (3.05, 3.74)	<.001
Activity	2.26 (1.46, 3.07)	<.001	4.68 (4.22, 5.14)	<.001
Impact	1.23 (0.8, 1.65)	<.001	2.6 (2.24, 2.95)	<.001
Symptom	1.68 (1.2, 2.16)	<.001	3.7 (3.35, 4.05)	<.001
SF-36 Physical Function	-0.72 (-1.05, -0.39)	<.001	-1.53 (-1.81, -1.24)	<.001
SF-36 Mental	-0.21 (-0.55, 0.13)	0.220	-0.02 (-0.33, 0.33)	0.920
6MWD (feet)	-35.66 (-47.6, -23.73)	<.001	-55.3 (-60.61, -49.99)	<.001
Resting SpO <sub>2</sub> %	-0.18 (-0.36, 0)	0.045	-0.25 (-0.34, -0.16)	<.001

Total population (n=1564) was utilized in this analysis. Associations are per 10% decrease in percent predicted KCO or percent predicted FEV<sub>1</sub>. Models include age, sex, BMI categories, ethnicity, education, smoking pack years, smoking status, anemia status, diabetes status, congestive heart failure status, sleep apnea status, % predicted FEV<sub>1</sub>, and % predicted KCO. *95% CI:* 95% confidence interval; *CAT:* COPD Assessment Test; *SGRQ:* St. George's Respiratory Questionnaire; *SF-36:* Short Form 36-item survey; *6MWD:* six-minute walk distance; *SpO*<sub>2</sub> %: oxygen saturation


Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

e-Table 4. Percent Predicted KCO and FEV1 a	associated with Exacerbations
---	-------------------------------

	KCO % predi	KCO % predicted		icted
Outcome	Rate ratio (95% CI)	p-value	Rate ratio (95% CI)	p-value
Any exacerbations	1.06 (1, 1.12)	0.054	1.23 (1.19, 1.28)	<.001
Moderate exacerbations	1.04 (0.97, 1.14)	0.261	1.20 (1.16, 1.25)	<.001
Severe exacerbations	1.11 (1.05, 1.18)	< 0.001	1.30 (1.22, 1.39)	<.001


Associations are per 10% decrease in percent predicted KCO or percent predicted FEV<sub>1</sub>. Exacerbation models (N=1806) include age, sex, ethnicity, BMI categories, education, pack years, smoking status, diabetes status, anemia status, congestive heart failure status, sleep apnea status, emphysema as a categorical variable (missing data,  $\leq 5\%$  LAA-950, >5% LAA-950), % predicted KCO, and % predicted FEV<sub>1</sub>. Any exacerbation refers to all episodes requiring antibiotics or steroids, moderate refers to only those episodes not resulting in an ER visit or hospitalization, and severe refers to those requiring an ER visit or hospitalization. *95% CI:* 95% confidence interval

e-Figure 1. Scatterplot of DLCO and Percent Emphysema (%LAA-950)



Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.

e-Figure 2. Association between severe reduction in DLCO and FEV1 with Exacerbations



Association between categories of FEV<sub>1</sub> and DLCO and self-reported rate of exacerbations. Any exacerbation refers to all exacerbations requiring antibiotics or steroids. Moderate exacerbation refers to any exacerbation requiring antibiotics or steroids but did not result in hospitalization. Groups are defined as reference (FEV<sub>1</sub> and DLCO both >50% predicted), DLCO impaired (FEV<sub>1</sub> >50% and DLCO  $\leq$ 50%), FEV<sub>1</sub> impaired (FEV<sub>1</sub>  $\leq$ 50% and DLCO >50%), and both impaired (FEV<sub>1</sub> and DLCO  $\leq$ 50%). Model is adjusted for age, sex, ethnicity, BMI categories, smoking pack years, anemia status, diabetes status, congestive heart failure status, sleep apnea status, and emphysema as a categorical variable (missing,  $\leq$ 5% LAA-950, >5% LAA-950). *RR:* Rate Ratio; *95% CI:* 95% confidence interval